Clinical analysis of bleeding and thrombotic events in haematological-oncology patients with severe thrombocytopenia and a high risk of thrombosis

Jing Wang, Miaomiao Gou, Fang Xu, Bin Chen, Shu Wang, Qiumei Shi, Qiuling Li, Jing Yu, Lan Zhang, Meiqi Yang, Jiao Tang, Yan Deng, Yan XiaoScientific 2024 · DOI

Abstract

For haematological neoplasm patients with a high risk of venous thromboembolism (VTE), severe thrombocytopenia, and high Charlson Comorbidity Index (CCI) scores, risk prevention and control of bleeding take precedence over thrombosis prophylaxis. However, prophylactic anticoagulation is still recommended for patients with lymphoma assessed at high risk for VTE and with platelet counts of at least 42.5 × 10⁹/L.

Introduction

In the field of hematological oncology, clinicians often face a "catch-22": patients are frequently at high risk for dangerous blood clots (Venous Thromboembolism, or VTE) due to the nature of their cancer and medical interventions, yet they also suffer from severe thrombocytopenia (low platelet counts), which makes them prone to uncontrolled bleeding.

Current clinical guidelines are often conservative, recommending that anticoagulants be avoided once platelet counts drop below 50 × 10⁹/L. However, thrombotic events still occur below this threshold. This study investigates the risk factors for this dual-threat scenario—known as Thrombohemorrhagic Syndrome (TSH)—to help clinicians decide when the risk of a clot outweighs the risk of a bleed.

Methods

The researchers conducted a retrospective study at Mianyang Central Hospital in China, analyzing data from a cohort of 446 patients admitted between July 2022 and June 2023.

Inclusion Criteria: * High VTE risk identified by a Caprini score ≥ 5. * Platelet counts < 50 × 10⁹/L at admission. * No prior prophylactic anticoagulation.

Flowchart of patient inclusion, exclusion, and clinical grouping.

The team used univariate and multivariate logistic regression to isolate independent risk factors and employed Receiver Operating Characteristic (ROC) curves to determine if a specific platelet count could predict thrombotic events.

Key Insights and Results

Risk Factor Divergence

The study confirmed that low platelets do not guarantee safety from clots; 14 patients in the high-risk group developed thrombosis during their stay. The factors driving bleeding were found to be distinct from those driving clots:

  • Bleeding Risk: Closely tied to a high CCI score (OR=1.331). Conversely, having lymphoma (OR=0.122) or a higher minimum platelet count (OR=0.925) acted as protective factors.
  • Thrombosis Risk: Driven by medical interventions and history, including a history of thrombosis (OR=17.284), use of two-lumen catheters (OR=7.852), and sedation (OR=34.969).

The 42.5 × 10⁹/L Threshold

A critical finding was the predictive power of platelet counts. While 50 × 10⁹/L is the traditional clinical threshold for concern, statistical analysis (AUC 0.735) identified 42.5 × 10⁹/L as a significant threshold where the risk of thrombosis becomes predictable.

Comparison of laboratory parameters across clinical events, showing significant differences in platelet counts (P=0.007).

Interestingly, lymphoma patients were significantly less likely to bleed compared to those with myeloid tumors, suggesting they may be safer candidates for blood thinners even with lower platelet counts.

Conclusion and Recommendations

For haematological-oncology patients with severe thrombocytopenia and high CCI scores, bleeding prevention remains the priority. However, for the specific subgroup of lymphoma patients at high risk for VTE, prophylactic anticoagulation is likely safe and recommended if their platelet count is at least 42.5 × 10⁹/L.

While these findings offer a promising new clinical benchmark, the authors emphasize the need for prospective, multi-center trials to validate this threshold for widespread use.

Summary updated

Abstract

For haematological neoplasm patients with a high risk of venous thromboembolism (VTE), severe thrombocytopenia and high CCI scores, risk prevention and control of bleeding take precedence over thrombosis prophylaxis. Prophylactic anticoagulation is still recommended for patients with lymphoma assessed at high risk for VTE and with platelet counts of at least 42.5 × 10<sup>9</sup>/L.
BibTeX
@inproceedings{wang2024clinical,
  author = {Jing Wang and Miaomiao Gou and Fang Xu and Bin Chen and Shu Wang and Qiumei Shi and Qiuling Li and Jing Yu and Lan Zhang and Meiqi Yang and Jiao Tang and Yan Deng and Yan Xiao},
  title = {{Clinical analysis of bleeding and thrombotic events in haematological-oncology patients with severe thrombocytopenia and a high risk of thrombosis}},
  booktitle = {Scientific},
  year = {2024},
  doi = {10.1038/s41598-024-75895-z},
}
Figure